✦ LIBER ✦

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

✍ Scribed by Emmanouilides, Christos; Witzig, Thomas E.; Gordon, Leo I.; Vo, Katie; Wiseman, Gregory A.; Flinn, Ian W.; Darif, Mohamed; Schilder, Russell J.; Molina, Arturo

Book ID: 126614116
Publisher: Informa plc
Year: 2006
Tongue: English
Weight: 352 KB
Volume: 47
Category: Article
ISSN: 1042-8194
DOI: 10.1080/10428190500376076

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weight-Based Dosing of Yttrium 90 Ibritu

Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

✍ Wiseman, Gregory A.; Conti, Peter S.; Vo, Katie; Schilder, Russell J.; Gordon, L 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 106 KB

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

Combining Yttrium 90–Labeled Ibritumomab

Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma

✍ Winter, Jane N. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 246 KB

Biodistribution, radiation dosimetry and

Biodistribution, radiation dosimetry and scouting of90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using89Zr-ibritumomab tiuxetan and PET

✍ Saiyada N. F. Rizvi; Otto J. Visser; Maria J. W. D. Vosjan; Arthur van Lingen; O 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 284 KB

Yttrium 90–Labeled Ibritumomab Tiuxetan

Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma

✍ Gordon, Leo I.; Witzig, Thomas; Molina, Arturo; Czuczman, Myron; Emmanouilides, 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 128 KB

Improving survival in patients with tran

Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation

✍ Marielle J. Wondergem; Josee M. Zijlstra; Madelon de Rooij; Otto J. Visser; Pete 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB